You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Inhaled nisin as an emergency intervention against antibiotic sensitive or resist
SBC: AFG BIOSOLUTIONS, INC. Topic: N/ADESCRIPTION (provided by applicant): The deliberate release of Bacillus anthracis spores remains an imminent threat both in terms of bioterrorism and biowarfare. Individuals who inhale these spores are at extreme risk of infection and death from anthrax. C urrent prophylaxis and therapy in the event of B. anthracis spore inhalation fall into two categories. Vaccination to protect against future ex ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Integrating microbial signal transduction pathways and their metabolic targets
SBC: AGILE GENOMICS, LLC Topic: N/ADESCRIPTION (provided by applicant): Signal transduction systems regulate the majority of cellular activities including the metabolism, development, host-recognition, biofilm production, virulence, and antibiotic resistance of human pathogens. Thus, knowle dge of the proteins and interactions that comprise these communication networks is an essential component to furthering biomedical discovery. T ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Add-on module for ONCAD for diagnosing infiltrating lobular carcinoma
SBC: Alan Penn & Associates Inc Topic: N/ADESCRIPTION (provided by applicant): The specific aim of this study is to develop an add-on module for the ONCAD breast MRI CAD system that will provide radiologists with additional assistance when they have suspicion of the presence of infiltrating lobula r carcinoma (ILC). The proposed research will investigate the possibility of developing, training and evaluating an ILC- specific algorithm tha ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
PLATELET-BASED NANOPARTICLE THERAPY FOR PROSTATE CANCER
SBC: ANDROBIOSYS, INC. Topic: N/AThe goal of this proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform technology is a freeze-dried human platelet (Stasix particles) that contains super paramagnetic iron oxide (SPIO) nanoparticles. The pre-clinical model for validation is the angiogenic human vasculat ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Anti-Angiogenic and Tumorcidal Drugs Against Lung Carcinoma
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Lung cancer is the world's leading cause of cancer deaths, with conventional therapies offering very limited benefit. Therefore, novel therapeutic approaches to improve outcomes of this disease are critical. Recent adva nces in tumor cell biology have led to renewed interest and heightened optimism in the development of new therapeutics targeting receptor tyros ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
TGFb1 Receptor Inhibitors for Liver Fibrosis
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to t ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
PARP-1 Inhibitors as Therapy for the Treatment of Stroke
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prevention and treatment, but translation of these approaches into improved clinical outcomes has proved to be painfully slow. Preventive strategies focus primarily on reducing or controlling risk factors such as diabe ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Novel Therapeutic for Amyotrophic Lateral Sclerosis (ALS)
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Literature indicates that HGF via its cytoprotective and tissue-regenerative activities protects a number of organs against traumatic and/or ischemic injury and fibrotic/degenerative disease. We have evaluated the effec ts of BB3/Rf in preclinical models of ischemic stroke, hepatic, renal, pulmonary and myocardial ischemia-reperfusion injury including models of ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Potential of a Small Molecule Compound for Emphysema
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Emphysema is a major cause of death and disability afflicting approximately 2 million people, costing more than 2.5 billion in yearly health care expenses and causing or contributing to 100,000 deaths per year in the U nited States alone. The disease is characterized by destruction of the alveolar wall, permanent enlargement of the airspaces and loss of lung r ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Phase I Clinical Trial for BB3
SBC: Angion Biomedica Corp. Topic: N/ADESCRIPTION (provided by applicant): Percutaneous coronary intervention has become the mainstay for treatment of ST-segment elevation myocardial infarction (STEMI). Whereas early recanalization undoubtedly salvages myocardial tissue, reperfusion following prolonged ischemia exacerbates injury. Infarct size needs to be limited, because in patients with acute myocardial infarction (AMI) who do not ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health